MESALAMINE | A203817 | ACTAVIS LABORATORIES FL INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Shire Development LLC et al v. Watson Pharmaceuticals, Inc. et al 1 patentANDA 203817mesalamine | S.D. Fla. | 2012-05-08 | Terminated 2016-03-28 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$0.8138
per ea
Lowest NADAC/Unit
$0.8138
per ea
Brand NDCs
0
Generic NDCs
1
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00591224522MESALAMINE DR 1.2 GM TABLET | $0.8138 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.